TaiRx, Inc. receives Honorable Recognition at the 12th Taiwan National Innovation Award.
TFDA approved the IND of TaiRx anti-cancer drug via Fast Track review to start phase I clinical trial in Taiwan.

TaiRx, Inc., a pharmaceutical company, focuses on the development of novel therapeutics with unmet medical needs. We target cancer as our first priority. Our team has extensive experience and knowledge in new drug development. This allows us to expedite the drug development process of our identified drug candidates going from early development to regulatory IND/NDA approval.

Our drug portfolio focuses on treating serious diseases and spans from drugs that are in early stages of pre-clinical and clinical development as well as new formulation design in order to balance the risk in development and the overall value of our portfolio.